• Home
  • About
  • Capabilities
  • R&D
  • Investors
  • News
  • Careers
中文
  • Home
  • About
  • Capabilities
  • R & D
  • Investors
  • News
  • Careers
Mabwell Signed an Agreement with Junshi Biosciences

Release time:Aug 28, 2017

The "Recombinant Human Anti-TNF-α Monoclonal Antibody Injection Cooperative Development Agreement" was signed with Shanghai Junshi Bio-pharmaceutical Co., Ltd. to jointly conduct preclinical research of a recombinant human anti-TNF-α monoclonal antibody injection.

Hot News
  • Highlights in Poster Presentations of Mabwell at 2025 ASCO
  • Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO
  • Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
  • Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
  • Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
  • Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO
  • About Who We Are Leadership Milestone Awards Contact
  • Capabilities R&D Manufacturing Commericalization
  • R&D Products Pipeline High-tech Platforms R&D Progress
  • Investors Stock Information IR Contact
  • News Press Release
  • Careers Value Awards & Welfare

Follow us
on WeChat

Copyright ©2022 Mabwell (Shanghai) Bioscience Co., Ltd. 沪 ICP 备 17041957 号 Shanghai public network security:31011502008788

Legal Statement| Privacy Policy| 技术支持:予尚网络